Skip to main content

Advertisement

Table 2 Cardiovascular risk factors and treatment in early RA at baseline (T0) and after five years (T5)

From: Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study

Variables T0 (n= 700) T5 (n= 442)
Hypertension, n (%) 170 (24.5) 164 (37.4)***
BP systolic, mmHg 144.1 (22.6) 141.2 (21.8)**
BP diastolic, mmHg 82.7 (10.3) 81.0 (9.6)**
Diabetes mellitus, n (%) 48 (7.1) 41 (9.5)**
BMI 26.3 (4.5) 25.8 (4.3)*
Smoking, present, n (%) 196 (29.8) 92 (22.4)***
Smoking, ever, n (%) 451 (69.5) -
Previous CVE, n (%) 72 (10.4) -
s-Cholesterol, mmol/L 5.6 (1.1)1 na
s-HDL, mmol/L 1.5 (0.5)1 na
s-Triglycerides, mmol/L 1.5 (0.7)1 na
Statin treatment, n (%) 54 (8.1) 71 (16.4)***
NSAIDs, n (%) 386 (58.5) 357 (82.4)***
COX-2 inhibitors, n (%) 82 (12.3) 112 (25.7)***
Corticosteroids, ever, n (%) 197 (29.1) 367 (72.7)***
Corticosteroids, months (T0 to T5) - 22.3 (24.0)
DMARDs ≤3 months after inclusion, n (%) - 393 (88.9)
DMARDs, ever, n (%) - 429 (96.8)
DMARDs months (T0 to T5) - 51 (16.4)
Methotrexate ever, n (%) - 361 (81.5)
Biologicals, ever, n (%) - 62 (14.2)
  1. Mean (SD) or n (%).
  2. *** P < 0.001, ** P < 0.01, * P < 0.05, paired t-test, for all patients who had reached the five-year follow-up, that is, who had data at both baseline (T0) and at follow-up (T5). na, not analysed
  3. 1analysed at baseline or as soon as possible during follow-up
  4. BMI, Body mass index; BP, blood pressure; COX-2, cyclo-oxygenase-2; CVE, cardiovascular event; DMARDs, disease-modifying anti-rheumatic drugs; HDL, high-density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis